Background: Reported rates of Chlamydia trachomatis are on the rise contradicting the declining rates of C. trachomatis associated reproductive sequelae in Western countries. Population based evaluation of the real trend of C. trachomatis infection is important to contemplate prevention efforts. We studied C. trachomatis occurrence during the past 20 years in Finland comparing incidence rate data based on serology and reported C. trachomatis laboratory notifications.
Background
Chlamydia trachomatis is a major threat to the reproductive health of women [1] . National surveillance programs have largely failed to reduce the disease burden caused by C. trachomatis [2] . In the Nordic countries, incidence rates have increased between 1999 and 2005 [3] [4] [5] . In Finland, the incidence of reported C. trachomatis infections increased by 60% over the last 10 years, peaking in the age group of 15-24 [6] . Since most chlamydial infections are asymptomatic [7] , true incidence may well be higher than that based on reports.
In a population based study, we recently reported declining C. trachomatis antibody prevalence rates [8] . The decrease was countrywide although small clusters of high prevalences were seen around large cities and in the Southeastern part of the country [8] . Similar trend has been reported from Japan [9] . These reports suggest that the control efforts may have been efficient.
To clarify the discordance between the reported infection rates to the National Infectious Disease Register (NIDR) and the seroprevalence rates, we studied the incidence rates of C. trachomatis infection by serology using paired serum bank samples. In order to have a better understanding of the real trend of C. trachomatis infections in the population, we compared incidence rate data based on serology and reported C. trachomatis laboratory notifications.
Methods

Finnish Maternity Cohort
More than 98% of pregnant women in Finland (altogether 750000) have participated in the serological screening for congenital infections (syphilis, HIV, and hepatitis B) during the first trimester. Approximately 50% of the women become pregnant again within 5 years of the first pregnancies and donate 2 nd blood samples to the Finnish Maternity Cohort (FMC) serum bank. The blood samples have been stored in FMC serum bank at the National Public Health Institute (KTL) since 1983 and the FMC serum bank comprises approximately 1.5 million serum samples.
A total of 275 505 women (< 29 years of age) with paired serum samples were identified for C. trachomatis antibody testing as previously described [8] . The FMC cohort was divided into 28 strata according to calendar year (by 3 year periods i.e. 1983-1985, 1986-1988, 1989-1991, 1992-1994, 1995-1997, 1998-2000, 2001-2003) and age (< 20, 20-22, 23-25 and 26-28) as described [8] . A random subsample of 200 or 400 women in each stratum was obtained. A total of 401 women were excluded because of missing data. Eventually, 7999 women were tested for C. trachomatis IgG-antibodies ( Table 1 ).
The study was approved by the institutional ethical committee and the FMC steering committee. [10] .
National Infectious Disease Register
C. trachomatis incidence rates were recorded in two age groups (≤ 24, and 25-29-year-olds) in four different time periods (1995-1997, 1998-2000, 2001-2003, 2004-2006) .
Serology
Serum IgG antibodies to C. trachomatis were analyzed in a single set of experiments by commercial enzyme immunoassay (EIA), as previously described [8] . The results were expressed as mean absorbance (optical density 450 mm) of duplicated samples minus the mean absorbance < 20  194  190  198  193  177  184  184  1320  20-22  195  195  193  199  187  194  185  1348  23-25  390  390  388  394  376  365  362  2665  26-28  393  397  384  389  366  367  370  2666  Total  1172  1172  1163  1175  1106  1110  1101  7999 of the reagent blank divided by the cut-off value. A value of greater than 1.4 was considered positive [8] .
Statistical analysis
Two youngest and two oldest age groups were combined for statistical analyses into two categories (women below 23 years and those between 23 and 28 years of age; Table  1 ). Baseline samples (first pregnancy serum sample) were used to calculate C. trachomatis seroprevalence rates. Differences in seroprevalence rates were tested using binomial test for differences in proportions. All 6632 women who were seronegative at the baseline were eligible for analysing the incidence rates. C. trachomatis incidence data was based on seroconversions i.e. the second sample of the baseline seronegative woman was positive. Incidence rates were estimated by the number of seroconversions divided by person years of follow-up. The time for each seroconversion was assumed to be in the midpoint of the two samplings. Crude incidence rate ratio with 95% confidence interval was calculated. Statistical analyses were performed using R 2.6.0 (R Development Core Team, Vienna, Austria) and SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA). 
C. trachomatis incidence rates based on seroconversions
A total of 161 seroconversions occurred among 6632 (2.4%) women who were seronegative at baseline. The rate of seroconversions varied from 3.4% to 5.7% in the younger age group and from 0.8% to 2.3% in the older age group.C. trachomatis incidence rates were higher in women who were < 23 years of age than in women between 23 and 28 years of age through out the whole time period although the difference decreased towards 2003 ( Figure 1B 
C. trachomatis incidence rates based on laboratory notifications
The point estimates based on the rates of the NIDR notifications were in line with C. trachomatis incidence rates based on seroconversions (Table 2 ). According to the laboratory notifications, C. trachomatis incidence increased in both age-groups (< 24 and 25-29 years of age) since 1995-1997 ( Table 2 ). The incidence rates were highest in women below 24 years of age with 1. 
Discussion
We showed that the C. trachomatis incidence rates based on serology were in line with the incidence rates based on laboratory notifications. The increasing incidence trends were at variance with decreasing C. trachomatis seroprevalence rates. Our results suggest that the true incidence rates can best be demonstrated by seroconversions detected in paired serum samples. The serum bank material used is likely to reveal the true population based incidence.
The number of cases with seroconversions followed the common u-shaped curve of reported C. trachomatis cases especially among the younger age group [1, 4, 10] . The conformity between the FMC and NIDR incidence rates indicates that the increasing trend is real. Testing of more individuals and using more sensitive diagnostic tests would not fully explain the increasing Chlamydia incidence rates.
The discrepancy between reported cases and seroprevalence rates is not easy to explain. Such discrepancy have earlier been reported from British Columbia during an extensive C. trachomatis control program [1] . Earlier diagnosis and treatment may lead to impaired immune response [1] which then reduces the overall seroprevalence rate in the population. Reinfection rates have not been analysed from the Finnish NIDR. However, increas- ing seroconversion rate suggests that the reported chlamydia rates are not explained merely by high reinfection rate.
The observed discrepancy between the incidence rate and seroprevalence is comparable with the declining trend of the long-term sequelae of C. trachomatis infection, e.g. PID, preterm delivery and ectopic pregnancy in Finland over the last ten years [11, 12] and suggest that the infection burden in the population would be decreasing. However, it can not be excluded that the increasing incidence rate reflects changes in the serotype distribution or type replacement with less pathogenic strains over time. More research is needed to know whether this could be a consequence of improved diagnosis and efficient treatment of symptomatic infections caused by virulent C. trachomatis serotypes linked with stronger symptoms [13] [14] [15] [16] [17] .
On the other hand, direct comparison of the FMC data and NIDR data is not straightforward. Most C. trachomatis infections occur in adolescents [5, 18, 19] with risk taking behaviour [20] . Although the FMC serum bank covers almost all pregnant women and is population based, it lacks infertile women and to a large part also adolescent women. Furthermore, contact tracing efforts probably lead to increasing test numbers and more asymptomatic cases reported to the NIDR.
Knowledge of C. trachomatis seroprevalence and incidence trends is extremely important since these trends reflect prevention efforts in the population. Furthermore, epidemiologic data are important not only for monitoring C. trachomatis infection trends but also for identification of breakthrough mutants [21] . A recent survey among elementary school students showed that the age of sexual debut is decreasing and condom use is inconsistent [22] . Increasing rates of reported C. trachomatis infection and the high incidence based on seroconversions fit into the picture. There is no national screening program in Finland although some maternity clinics routinely test women. Nevertheless, the Ministry of Social Affairs and Health has prepared a recommendation for opportunistic screening in Finland but significant reduction in the C. trachomatis rates is unlikely to take place unless systematic screening is implemented.
Conclusion
This study confirms the decline of C. trachomatis seroprevalence in Finland since the middle of 1990s'. Simultaneously demonstrated rising seroconversion rates in different individuals are in accordance with the reported laboratory notifications in the NIDR suggesting that the increasing infection rates are not only due to repeated infections. Based on our results, population-based C. trachomatis incidence rates can be demonstrated by seroconversions detected in paired serum samples. The discrepancy between the C. trachomatis incidence and seroprevalence trends warrants further studies. 
